Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry

Clinica Chimica Acta

Volumn 413, Issue 23-24, 2012, Pages 1839-1847

  Scheidweiler, Karl B ^a   Desrosiers, Nathalie A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Analytical method; Cannabinoid glucuronides; Cannabinoids; LCMSMS; Metabolites; Urine

Indexed keywords

11 HYDROXY DELTA9 TETRAHYDROCANNABINOL D3; 11 HYDROXYDRONABINOL; 11 NOR 9 CARBOXY DELTA9 TETRAHYDROCANNABINOL D9; 11 NOR 9 CARBOXY DELTA9 TETRAHYDROCANNABINOL GLUCURONIDE; ACETONITRILE; AMMONIUM ACETATE; CANNABIDIOL; CANNABIDIOL D3; CANNABIDIOL DERIVATIVE; CANNABINOID; CANNABINOL; DELTA9 TETRAHYDROCANNABINOL D3; DELTA9 TETRAHYDROCANNABINOL GLUCURONIDE; DRONABINOL; FREE CANNABINOID; GLUCURONIDATED CANNABINOID; GLUCURONIDE; METHANOL; TETRAHYDROCANNABINOL DERIVATIVE; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANNABIS SMOKING; ELECTROSPRAY MASS SPECTROMETRY; GLUCURONIDATION; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; NORMAL HUMAN; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; URINALYSIS; VALIDATION STUDY; ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; REPRODUCIBILITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; TIME; URINE;

ANALYTIC SAMPLE PREPARATION METHODS; CANNABINOIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; HUMANS; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TIME FACTORS; URINALYSIS;

EID: 84864917064     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.034     Document Type: Article

References (41)

1. Substance Abuse and Mental Health Services Administration, Results from the 2009 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, (eds.) NSDUH Series H-38A, 2010, Department of Health and Human Services (DHHS), Rockville, MD.
2. Lowe, R., Abraham, T., Darwin, W., Herning, R., Cadet, J., Huestis, M., Extended urinary delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 105 (2009), 24–32.
3. Goodwin, R.S., Darwin, W.D., Chiang, C.N., Shih, M., Li, S.-H., Huestis, M.A., Urinary elimination of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 32 (2008), 562–566.
4. Karschner, E., Schwilke, E., Lowe, R., et al. Do delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction 104 (2009), 2041–2048.
5. Karschner, E., Schwilke, E., Lowe, R., et al. Implications of plasma delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 33 (2009), 469–477.
6. Huestis, M.A., Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Pertwee, R.G., (eds.) Handbook of experimental pharmacology, volume 168, 2005, Springer, New York, 657–690.
7. Kemp, P.M., Abukhalaf, I.K., Manno, J.E., Manno, B.R., Alford, D.D., Abusada, G.A., Cannabinoids in humans. I. Analysis of delta9-tetrahydrocannabinol and six metabolites in plasma and urine using GC–MS. J Anal Toxicol 19 (1995), 285–291.
8. Kemp, P.M., Abukhalaf, I.K., Manno, J.E., et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19 (1995), 292–298.
9. Abraham, T.T., Lowe, R.H., Pirnay, S.O., Darwin, W.D., Huestis, M.A., Simultaneous GC–EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 31 (2007), 477–485.
10. Schwope, D.M., Karschner, E.L., Gorelick, D.A., Huestis, M.A., Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57 (2011), 1406–1414.
11. Skopp, G., Pötsch, L., Ganßmann, B., et al. Freie und glucuronidierte cannabinoide im urin—untersuchungen zur einschätzung des konsumverhaltens. Rechtsmedizin 10 (1999), 21–28.
12. Mareck, U., Haenelt, N., Geyer, H., et al. Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal 1 (2009), 505–510.
13. Schwope, D.M., Scheidweiler, K.B., Huestis, M.A., Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 401 (2011), 1273–1283.
14. Boldis, O., Kocsis, G., Gachalyi, A., Furesz, J., Gas chromatography–mass spectrometry-single ion monitoring measurement of 11-nor-delta9-tetrahydrocannabinol-carboxylic acid in urine. J Chromatogr Sci 41 (2003), 190–194.
15. Whitter, P.D., Cary, P.L., Leaton, J.I., Johnson, J.E., Automated extraction for the analysis of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in urine using a six-head probe hamilton microlab 2200 system and gas chromatography–mass spectrometry. J Anal Toxicol 23 (1999), 286–289.
16. Paul, B.D., Mell, L.D. Jr., Mitchell, J.M., McKinley, R.M., Irving, J., Detection and quantitation of urinary 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of tetrahydrocannabinol by capillary gas chromatography and electron impact mass fragmentography. J Anal Toxicol 11 (1987), 1–5.
17. Singh, J., Johnson, L., Solid-phase extraction of THC metabolite from urine using the Empore disk cartridge prior to analysis by GC–MS. J Anal Toxicol 21 (1997), 384–387.
18. Feng, S., ElSohly, M.A., Salamone, S., Salem, M.Y., Simultaneous analysis of delta9-THC and its major metabolites in urine, plasma, and meconium by GC–MS using an immunoaffinity extraction procedure. J Anal Toxicol 24 (2000), 395–402.
19. Crockett, D.K., Nelson, G., Dimson, P., Urry, F.M., Solid-phase extraction of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid from workplace urine drug-testing specimens with the cerex PolyCrom-THC column. J Anal Toxicol 24 (2000), 245–249.
20. Langen, M.C.J., de Bijl, G.A., Egberts, A.C.G., Automated extraction of 11-nor-delta9-tetrahydrocannabinol carboxylic acid from urine samples using the ASPEC XL solid-phase extraction system. J Anal Toxicol 24 (2000), 433–437.
21. Stout, P.R., Horn, C.K., Klette, K.L., Solid-phase extraction and GC–MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory. J Anal Toxicol 25 (2001), 550–554.
22. Jamerson, M.H., Welton, R.M., Morris-Kukoski, C.L., Klette, K.L., Rapid quantification of urinary 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid using fast gas chromatography–mass spectrometry. J Anal Toxicol 29 (2005), 664–668.
23. Moon, J.Y., Kim, J.Y., Moon, M.H., Chung, B.C., In, M.K., Choi, M.H., Validated gas chromatographic–mass spectrometric analysis of urinary cannabinoids purified with a calcium-hardened beta-cyclodextrin polymer. J Chromatogr A 1204 (2008), 87–92.
24. Skopp, G., Potsch, L., Stability of 11-nor-delta(9)-carboxy-tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem 48 (2002), 301–306.
25. Felli, M., Martello, S., Chiarotti, M., LC-MS-MS method for simultaneous determination of THCCOOH and THCCOOH-glucuronide in urine: application to workplace confirmation tests. Forensic Sci Int 204 (2011), 67–73.
26. Mareck, U., Haenelt, N., Geyer, H., et al. Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal 1 (2009), 505–510.
27. Gronewold, A., Skopp, G., A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int 210 (2011), e7–e11.
28. Krouwer, J.S., Rabinowitz, R., How to improve estimates of imprecision. Clin Chem 30 (1984), 290–292.
29. Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75 (2003), 3019–3030.
30. Shipkova, M., Armstrong, V.W., Oellerich, M., Wieland, E., Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25 (2003), 1–16.
31. Skopp, G., Potsch, L., An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 28 (2004), 35–40.
32. Grauwiler, S.B., Scholer, A., Drewe, J., Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B 850 (2007), 515–522.
33. Christophersen, A.S., Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 10 (1986), 129–131.
34. Halldin, M.M., Anderson, L.K.R., Widman, M., Hollister, L.E., Further urinary metabolites of delta9-tetrahydrocannabinol in man. Arzneimittelforchung 32 (1982), 1135–1138.
35. Halldin, M.M., Carlsson, S., Kanter, S.L., Widman, M., Agurell, S., Urinary metabolites of delta9-tetrahydrocannabinol in man. Arzneimittelforchung 32 (1982), 764–768.
36. Williams, P.L., Moffat, A.C., Identification in human urine of delta9-tetrahydrocannabinol- 11-oic glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32 (1980), 445–448.
37. Wall, M.E., Sadler, B.M., Brine, D., Taylor, H., Perez-Reyes, M., Metabolism, disposition, and kinetics of delta9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34 (1983), 352–363.
38. Skopp, G., Potsch, L., Mauden, M., Richter, B., Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-delta9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci Int 126 (2002), 17–23.
39. Huestis, M.A., Cone, E.J., Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22 (1998), 445–454.
40. Smith, M.L., Barnes, A.J., Huestis, M.A., Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol 33 (2009), 185–189.
41. Schwilke, E.W., Gullberg, R.G., Darwin, W.D., et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 106 (2011), 499–506.